Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “buy” rating reissued by Canaccord Genuity in a research report issued to clients and investors on Tuesday.

A number of other equities analysts have also recently weighed in on KPTI. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th. Wedbush reissued an “outperform” rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, August 4th. HC Wainwright began coverage on shares of Karyopharm Therapeutics in a research report on Thursday, August 18th. They issued a “buy” rating and a $15.00 price target for the company. Jefferies Group raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the company from $9.00 to $12.00 in a research report on Tuesday, August 30th. Finally, S&P Equity Research decreased their price target on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $16.04.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.32 on Tuesday. The firm’s 50-day moving average price is $8.70 and its 200-day moving average price is $8.27. Karyopharm Therapeutics has a 12-month low of $4.83 and a 12-month high of $19.41. The company’s market capitalization is $335.42 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.12. On average, analysts expect that Karyopharm Therapeutics will post ($3.22) EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Palo Alto Investors LLC boosted its position in Karyopharm Therapeutics by 1.3% in the second quarter. Palo Alto Investors LLC now owns 3,139,433 shares of the company’s stock valued at $21,066,000 after buying an additional 41,288 shares during the last quarter. Wellington Management Group LLP boosted its position in Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock valued at $11,323,000 after buying an additional 1,096,029 shares during the last quarter. BlackRock Fund Advisors boosted its position in Karyopharm Therapeutics by 7.2% in the third quarter. BlackRock Fund Advisors now owns 1,147,261 shares of the company’s stock valued at $11,163,000 after buying an additional 77,482 shares during the last quarter. Vanguard Group Inc. boosted its position in Karyopharm Therapeutics by 18.5% in the second quarter. Vanguard Group Inc. now owns 816,444 shares of the company’s stock valued at $5,478,000 after buying an additional 127,714 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Karyopharm Therapeutics by 1.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 539,090 shares of the company’s stock valued at $5,245,000 after buying an additional 8,274 shares during the last quarter. 55.71% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.